Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1287 - Analysis of study results of CA-125 and HE 4 at ovarian cancer


20 Dec 2015


Poster presentation 2


Visola Navruzova


Annals of Oncology (2015) 26 (suppl_9): 80-84. 10.1093/annonc/mdv525


V. Navruzova1, N.S. Yuldasheva2, O.M. Akhmedov2

Author affiliations

  • 1 Gynaecology, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ
  • 2 Gynecology, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ


Abstract 1287


Ovarian cancer remains the leading cause of death among diseases of the female genital organs. Absolute majority of patients with ovarian cancer stage lll-IV are admitted to oncological clinics. Determination of CA125 at ovarian cancer does not always solve the problem of early diagnosis; there is the necessity of finding new oncofatal antigens or combinations of markers.


Serum from 52 patients with diagnosed serous ovarian cancer was analyzed for CA-125 and HE4 levels in National Cancer Research Center of the Republic of Uzbekistan. From 52 patients in 10 patients was revealed stage IIIA process, in 9 patients - stage IIIB, in 22 patients - stage INC and in 11 patients - stage IV. The mean age of patients was 58.4 ± 6.7 years. The level of tumor markers CA-125 and HE 4 determined before treatment and after treatment in the dynamics (8 to 32 months) every 3 months.


We studied the results of each tumor marker in univariate as well as multivariate analysis. Individually, the results were different, false-positive and false-negative values differed. Analysis of combined use of CA-125 and HE 4 showed that tumor markers complemented each other, the efficiency of detection of early recurrence or metastasis increased to 27.5% in a ratio of the use of each tumor marker individually (CA -125 for 31.2%, and HE 4 for 25.1%).


The use of CA-125 or HE 4 at ovarian cancer is not always specific and reasonably sensitive at early stages. The combination of CA-125 and HE 4 levels was significantly increased the efficiency of early detection of recurrences.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings